Nonarteritic anterior ischemic optic neuropathy, or NAION, cases involve Mounjaro, Zepbound, Ozempic, and Wegovy, as well as other glucagon-like peptide-1 receptor agonists (GLP-1RAs), according to an April 2026 medical study report published online by JAMA Network Open.
This medical study report, “GLP-1 Receptor Agonists or SGLT2 Inhibitors and Nonarteritic Anterior Ischemic Optic Neuropathy“, presents a 2025 analysis of 2017 – 2023 health records from the US Department of Veterans Affairs (VA) done to investigate the rate of NAION cases involving Mounjaro, Zepbound, Ozempic, Wegovy, and other GLP-1RA drugs.
When all was said and done, the authors of this 2026 medical study report about NAION concluded:
In this large cohort study, [Mounjaro, Zepbound, Ozempic, Wegovy, and other GLP-1RA drugs] use was associated with a modestly increased risk of NAION compared with [sodium-glucose cotransporter-2 inhibitors (SGLT2i) drugs] use. While the absolute risk remains low, the specificity of this finding may warrant heightened vigilance.
NAION cases that involve Mounjaro, Zepbound, Ozempic, Wegovy, and other GLP-1RA drugs are a drug safety issue that first came to light in the second part of 2024. For example, two large medical studies from Denmark found that people who used Ozempic had double the risk of developing NAION, which can cause vision loss and blindness.
In the past couple of years, NAION cases involving Mounjaro, Zepbound, Ozempic, Wegovy, and other GLP-1RA drugs have been filed against the responsible pharmaceutical companies for their failure to warn patients and doctors about the risk of developing NAION.
For an introduction to NAION cases involving Mounjaro, Zepbound, Ozempic, and Wegovy and those drug injury lawsuits, here are links to a couple of Drug Injury Law website pages:
- Eye-related Side Effects of Ozempic, Wegovy, and Rybelsus With Vision Loss
- Zepbound and Mounjaro Eye Side Effect NAION Information Page
We are investigating NAION cases that involve Mounjaro, Zepbound, Ozempic, Wegovy, and other GLP-1RA drugs for patients as drug injury lawsuits seeking legal compensation for their vision loss. We point out that those NAION lawsuits would not be filed against the patients’ doctors because the pharmaceutical company failed to warn about the NAION eye side effect associated with their drug.
[Read the article in full at Drug Injury Watch]Mounjaro / Zepbound
Free Case Evaluation
Strictly Confidential, No Obligation
Ozempic / Wegovy
Free Case Evaluation
Strictly Confidential, No Obligation